Halozyme Therapeutics (HALO) Return on Capital Employed (2011 - 2026)

Halozyme Therapeutics (HALO) has 16 years of Return on Capital Employed data on file, last reported at 22.9% in Q1 2026.

• On a quarterly basis, Return on Capital Employed fell 728.0% year-over-year to 22.9% in Q1 2026; TTM through Mar 2026 was 22.9%, a 728.0% decrease from a year earlier, with the FY2025 full-year figure at 22.15%, down 920.0% from the prior year.
• Return on Capital Employed for Q1 2026 stood at 22.9%, up from 21.36% in the prior quarter.
• Over the last five years, Return on Capital Employed for HALO reached as high as 56.71% in Q3 2025 and fell as low as 14.56% in Q3 2022.
• Historically, Return on Capital Employed has averaged 24.33% across 5 years, with a median of 22.69% in 2024.
• Across the five-year window, Return on Capital Employed plunged 1536 bps in 2022 and jumped 3206 bps in 2025, its largest moves.
• Year by year, Return on Capital Employed stood at 15.53% in 2022, then grew by 28 bps to 19.85% in 2023, then jumped by 42 bps to 28.26% in 2024, then retreated by 24 bps to 21.36% in 2025, then gained by 7 bps to 22.9% in 2026.
• Per Business Quant data, the three most recent Return on Capital Employed figures were 22.9% in Q1 2026, 21.36% in Q4 2025, and 56.71% in Q3 2025.